Log In
BCIQ
Print this Print this
 

BMS-936557 (formerly MDX-1100)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionUltiMAb-derived human mAb against chemokine CXC motif ligand 10 (CXCL10; IP-10)
Molecular Target Chemokine CXC motif ligand 10 (CXCL10) (IP-10)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat ulcerative colitis (UC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,400.0M

$2,400.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/07/2009

$2,400.0M

$2,400.0M

0

Get a free BioCentury trial today